Holen Sie sich die Stockscreener-App
7.395
3.93%
0.275
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Amicus Therapeutics Inc. Recovery Likely Here’s What Data ShowsPortfolio Update Report & Daily Technical Stock Forecast Reports - beatles.ru
Using economic indicators to assess Amicus Therapeutics Inc. potential2025 Technical Overview & Stock Portfolio Risk Management - Newser
Published on: 2025-08-14 05:57:55 - Newser
Will earnings trigger a reversal in Amicus Therapeutics Inc.2025 Performance Recap & Accurate Entry and Exit Point Alerts - Newser
Connor Clark & Lunn Investment Management Ltd. Buys 483,698 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
What institutional flow reveals about Amicus Therapeutics Inc.2025 Earnings Impact & Expert Approved Momentum Trade Ideas - Newser
Regression analysis insights on Amicus Therapeutics Inc. performanceDividend Hike & AI Driven Stock Price Forecasts - Newser
Heatmap Data Shows High Activity in Amicus Therapeutics Inc. Sector [Trade Analysis Summary]Weekly Market Pulse Updates - 선데이타임즈
Can trapped investors hope for a rebound in Amicus Therapeutics Inc.Pattern Recognition Tool for ROI Investors - Newser
Has Amicus Therapeutics Inc. formed a bullish divergenceFree Daily Smart Money Movement Monitor - Newser
Applying Wyckoff theory to Amicus Therapeutics Inc. stockTrade Alert System with Volume Analysis - Newser
Why is Amicus Therapeutics Inc. stock going downMassive Profit Potential Picks - mustnews.co.kr
Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% HigherShould You Buy? - MarketBeat
What candlestick patterns are forming on Amicus Therapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
How Efficient Is Amicus Therapeutics Inc. at Controlling Operating CostsFree ROI Boosting Trade Opportunity Calendar - Newser
Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wall Street Zen Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy - MarketBeat
XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? - Yahoo Finance
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Upgraded at Wall Street Zen - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat
Amicus Therapeutics Inc. Rebound Backed by Sentiment ShiftFundamental + Technical Hybrid Stock Tips Shared - metal.it
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... By GuruFocus - Investing.com Canada
What are the latest earnings results for Amicus Therapeutics Inc.Invest in stocks with strong fundamentals - Jammu Links News
Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful portfolio management tools - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News
What catalysts could drive Amicus Therapeutics Inc. stock higher in 2025Phenomenal trading returns - Jammu Links News
When is Amicus Therapeutics Inc. stock expected to show significant growthDiscover stocks with massive upside potential - Jammu Links News
What are the technical indicators suggesting about Amicus Therapeutics Inc.Get daily expert analysis on top stocks - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
What drives Amicus Therapeutics Inc. stock priceMaximize your portfolio’s growth with expert tips - Jammu Links News
How does Amicus Therapeutics Inc. compare to its industry peersExceptional market performance - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stock outlookIntraday Price Forecast Using Volume Models - Newser
Should I hold or sell Amicus Therapeutics Inc. stock in 2025Unlock exclusive stock market insights - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Is it the right time to buy Amicus Therapeutics Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Amicus Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mesirow Financial Investment Management Inc. Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Victory Capital Management Inc. Purchases 82,691 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics Reports Strong Growth Amid Strategic Advances - The Globe and Mail
Amicus Therapeutics' Q2 Performance: A Glimpse into Rare Disease Growth and Strategic Risks - AInvest
Amicus Therapeutics Surpasses $1B Target Revenues with DMX-200 License Agreement - AInvest
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha
FOLD Q2 Earnings Miss Mark, Revenues Beat On Higher Product Sales - Barchart.com
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates - MSN
0.07%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):